Health & Biotech

'Dumpster diving' for small-cap opportunities is only for the bold, but the exercise can produce some tasty morsels at a…

Morgans analyst Scott Power notes there's a risk-off sentiment among investors with concerns about US tariffs as ASX health stocks…

Race Oncology has been given ethics approval for a Phase I trial of RC220 bisantrene alone and in combination with…

Idiopathic pulmonary fibrosis is a progressive and life-threatening lung disease but there are ASX companies bringing hope to sufferers.

Proteomics International aptly has chosen World Kidney Day to launch its predictive test for diabetic kidney disease locally.

Helping its goal to become a major global dermatology player, Botanix has been elevated into the S&P/ASX 300 index after…

Tim Boreham chats with Imagion Biosystems executive chair Bob Proulx about its emerging alternative for imaging the human body.

The deepening market sell-off has not spared many of the big commercialised, profitable biotechs. But the question is whether they…

Botanix Pharmaceuticals Howie McKibbon drops by the Stockhead TV studio for an update on the company's inclusion on the ASX300. 

Recce has opted to carry out its phase III diabetic foot injury trial in Indonesia – which looks a safer…